Summer Sale Get Elite for just $199.50

00

Days

00

Hours

00

Mins

00

Sec

Claim Now

Minerva Neurosciences, Inc

Contributing Author

Recent Articles by Minerva Neurosciences, Inc

Jun-01	Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs NERV GlobeNewswire
May-18	Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference NERV -9.02% NERV -8.02% GlobeNewswire
May-05	Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates NERV GlobeNewswire
Apr-02	Minerva Announces Leadership Transition NERV -5.71% GlobeNewswire
Mar-31	Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia NERV NERV -7.05% GlobeNewswire
Mar-25	Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026 NERV GlobeNewswire
Mar-12	Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum NERV +5.34% GlobeNewswire
Mar-11	Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates NERV -8.06% GlobeNewswire
Mar-04	Minerva Neurosciences to Participate in The Citizens Life Sciences Conference NERV GlobeNewswire
Jan-26	Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality - Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026 NERV GlobeNewswire
Nov-19	Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors NERV GlobeNewswire
Nov-05	Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates NERV GlobeNewswire
Oct-21	Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved NERV +140.98% GlobeNewswire
Aug-14	Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results NERV NERV +25.35% GlobeNewswire
May-13	Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates NERV GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)